

**methylphenidate prolonged-release capsule  
(Medikinet XL<sup>®</sup>)**

**No. (388/07)**

**Flynn Pharma Ltd**

**Product Update**

8 June 2007

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

Methylphenidate prolonged-release capsule (Medikinet XL<sup>®</sup>) is accepted for restricted use within NHS Scotland as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children over 6 years of age when remedial measures alone prove insufficient.

Like other modified release methylphenidate formulations, it should be considered second line and used for patients requiring methylphenidate in the morning and afternoon when administration of a midday dose is problematic or inappropriate. Treatment should be under the supervision of a specialist in childhood behaviour disorders. The pharmacokinetic profile of Medikinet XL<sup>®</sup> differs from those of other modified release formulations of methylphenidate.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 9 May 2007*

**Chairman,  
Scottish Medicines Consortium**